Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

Todd Neale

October 02, 2024

News Daily News

Biologic Winrevair Wins FDA Approval for Treatment of PAH

L.A. McKeown

March 27, 2024

News Daily News

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

L.A. McKeown

February 02, 2024

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Michael O'Riordan

May 12, 2021

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

Todd Neale

December 23, 2019

News Daily News

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

Todd Neale

August 19, 2019

News Daily News

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Michael O'Riordan

July 20, 2018

Advertisement

FDA Approves Triple Therapy Polypill for High Blood Pressure

Coverage and Use of Impella and Watchman: A Tale of Four Countries

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

Biologic Winrevair Wins FDA Approval for Treatment of PAH

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Funding the Future: How Industry Support for CV Trials Could Evolve

FDA Approves Two Generic Versions of Apixaban

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content